Esperoct 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0020/G 
This was an application for a group of variations. 
05/10/2023 
n/a 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
X/0016 
Annex I_2.(c) Change or addition of a new 
20/07/2023 
15/09/2023 
SmPC, 
strength/potency 
Labelling and 
PL 
WS/2480 
This was an application for a variation following a 
13/07/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
PSUSA/10782
Periodic Safety Update EU Single assessment - 
06/07/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
turoctocog alfa pegol 
II/0013 
Update of section 4.2 of the SmPC in order to delete 
23/02/2023 
24/03/2023 
SmPC and PL 
Submission of the final results from study NN7088-3908 
the statement in reference to previously untreated 
patients (PUPs) and section 5.1 of the SmPC in order 
to update information based on final results from 
which is an open-label single-arm multicentre non-
controlled phase 3a trial investigating safety and efficacy of 
turoctocog alfa pegol in prophylaxis and treatment of 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
study NN7088-3908; this is an open-label single-arm 
bleeding episodes in previously untreated paediatric 
multicentre non-controlled phase 3a trial 
investigating safety and efficacy of turoctocog alfa 
pegol (N8-GP) in prophylaxis and treatment of 
bleeding episodes in previously untreated paediatric 
patients with severe haemophilia A. In addition, the 
MAH took the opportunity to introduce minor 
editorial changes to the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
patients with severe haemophilia AUpdate of Section 4.2 to 
remove the statement. Section 4.2 and 5.1 have been 
updated accordingly. In addition, information on Factor VIII 
inhibition as “very common” event in PUPs is included in 
section 4.8 of the SmPC.  
Amendments are requested. For more information, please 
refer to the SmPC. 
PSUSA/10782
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202206 
turoctocog alfa pegol 
IB/0017/G 
This was an application for a group of variations. 
30/11/2022 
24/03/2023 
SmPC 
PI was updated to reflect extension of the shelf life of the 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
finished product Esperoct® unopened vial, before 
reconstitution from 30 months to 36 months when stored 
at 5°C. 
IB/0014 
B.II.h.z - Adventitious Agents Safety - Other 
12/08/2022 
n/a 
variation 
II/0010 
Update of sections 4.4 and 4.8 of the SmPC to add a 
21/07/2022 
24/03/2023 
SmPC, 
Update of sections 4.4 and 4.8 of the SmPC to add a new 
new warning and update the list of ADRs based on a 
Labelling and 
warning and update the list of ADRs based on a validated 
validated safety signal concerning a lack of factor 
PL 
safety signal concerning a lack of factor VIII activity in 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VIII activity in patients switching from a similar 
factor VIII product to Esperoct. The Package Leaflet 
is updated accordingly. In addition, the MAH took the 
opportunity to introduce minor editorial changes to 
the PI and to align it with the latest QRD template 
version 10.2. The RMP version 2.1 has also been 
submitted. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
patients switching from a similar factor VIII product to 
Esperoct. 
For more information, please refer to the Summary of 
Product Characteristics. 
PSUSA/10782
Periodic Safety Update EU Single assessment - 
07/07/2022 
n/a 
PRAC Recommendation - maintenance 
/202112 
turoctocog alfa pegol 
WS/2227 
This was an application for a variation following a 
02/06/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
WS/2136 
This was an application for a variation following a 
28/04/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.c.1.c - Change in immediate packaging of the AS 
- Liquid ASs (non sterile) 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10782
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202106 
turoctocog alfa pegol 
PSUSA/10782
Periodic Safety Update EU Single assessment - 
08/07/2021 
n/a 
PRAC Recommendation - maintenance 
/202012 
turoctocog alfa pegol 
PSUSA/10782
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202006 
turoctocog alfa pegol 
IB/0006 
B.I.d.1.z - Stability of AS - Change in the re-test 
07/01/2021 
n/a 
period/storage period or storage conditions - Other 
variation 
IB/0004 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/08/2020 
25/08/2020 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
PSUSA/10782
Periodic Safety Update EU Single assessment - 
09/07/2020 
n/a 
PRAC Recommendation - maintenance 
/201912 
turoctocog alfa pegol 
II/0002 
B.II.f.1.c - Stability of FP - Change in storage 
30/01/2020 
25/08/2020 
SmPC, 
conditions for biological medicinal products, when the 
stability studies have not been performed in 
accordance with an approved stability protocol 
Labelling and 
PL 
WS/1681 
This was an application for a variation following a 
17/10/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 6/6 
 
 
 
 
 
 
 
